RE:RE:RE:RE:RE:Merck USA (MSD) acquires Phase 2 biotech for US$ 10.8 Bln.It has only recently been accepted that there is a need to better understand the complex tumor microenvironment to more accurately determine prognosis and design therapeutic strategies capable of rendering tumors susceptible to immunotherapy and the immunologic effects of conventional therapies.
ONCY's pelareorep is able to address the problem of the tumor microenvironment (TME) and in so doing is able to offer a increasingly demonstrated solution to a predictive and prognostic combination drug therapeutic strategy that includes the addition of PD-(L)1 immune checkpoint inhibitors, CAR-T, bispecific and antibody drug conjugate (ADC) therapy, and CDK4,6 and PARP inhibitor small molecules, as several examples.